Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-03-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/0963689721999615 |
id |
doaj-c65a3adc6dde4490921caed5521323c5 |
---|---|
record_format |
Article |
spelling |
doaj-c65a3adc6dde4490921caed5521323c52021-03-22T22:33:26ZengSAGE PublishingCell Transplantation1555-38922021-03-013010.1177/0963689721999615Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell LymphomasGu Zhenyang0Li Nainong1Wu Xiaoxiong2Wang Maihong3Fu Xiaorui4Wang Zhao5Ren Hanyun6Li Yuhang7Li Xiaofan8Wu Yamei9Liu Yao10Zhang Mingzhi11Wang Yini12Liu Daihong13Dong Yujun14Hu Liangding15Huang Wenrong16 Department of Hematology, Chinese PLA General Hospital, Beijing, China Department of Hematology, Fujian Institute of Hematology, Fuzhou, China Department of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Hematology, Peking University First Hospital, Beijing, China Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China Department of Hematology, Fujian Institute of Hematology, Fuzhou, China Department of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Department of Hematology, Chinese PLA General Hospital, Beijing, China Department of Hematology, Peking University First Hospital, Beijing, China Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China Department of Hematology, Chinese PLA General Hospital, Beijing, ChinaThe number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT ( n = 20) or MSD-HSCT ( n = 32). All Haplo-HSCT recipients received antithymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis. The median follow-up for all survivors was 38 months. The 100-day cumulative incidence of grade II to IV acute GVHD was similar (19% in the MSD-HSCT group versus 28% in the Haplo-HSCT group, P = 0.52). The 2-year cumulative incidence of chronic GVHD (limited and extensive) after Haplo-HSCT (30%) was also similar with that in the MSD-HSCT group (50%, P = 0.15). The 3-year relapse rates (33% vs 27%, P = 0.84) and non-relapse mortality (21% vs 22%, P = 0.78) did not differ between these two groups. There were also no differences in 3-year overall survival (OS) (48% vs 50%, P = 0.78) and progression-free survival (47% vs 51%, P = 0.95) between these two groups. On multivariate analysis, prognostic index for T-cell lymphoma (PIT) score (higher than 1: hazard ratio [HR], 4.0; P = 0.003) and disease status (stable or progression disease before HSCT: HR, 2.8; P = 0.03) were independent variables associated with worse OS. We concluded that ATG-based haplo-HSCT platform could work as an alternative to MSD-HSCT for patients with PTCLs.https://doi.org/10.1177/0963689721999615 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gu Zhenyang Li Nainong Wu Xiaoxiong Wang Maihong Fu Xiaorui Wang Zhao Ren Hanyun Li Yuhang Li Xiaofan Wu Yamei Liu Yao Zhang Mingzhi Wang Yini Liu Daihong Dong Yujun Hu Liangding Huang Wenrong |
spellingShingle |
Gu Zhenyang Li Nainong Wu Xiaoxiong Wang Maihong Fu Xiaorui Wang Zhao Ren Hanyun Li Yuhang Li Xiaofan Wu Yamei Liu Yao Zhang Mingzhi Wang Yini Liu Daihong Dong Yujun Hu Liangding Huang Wenrong Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas Cell Transplantation |
author_facet |
Gu Zhenyang Li Nainong Wu Xiaoxiong Wang Maihong Fu Xiaorui Wang Zhao Ren Hanyun Li Yuhang Li Xiaofan Wu Yamei Liu Yao Zhang Mingzhi Wang Yini Liu Daihong Dong Yujun Hu Liangding Huang Wenrong |
author_sort |
Gu Zhenyang |
title |
Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas |
title_short |
Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas |
title_full |
Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas |
title_fullStr |
Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas |
title_full_unstemmed |
Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas |
title_sort |
myeloablative haploidentical transplant as an alternative to matched sibling transplant for peripheral t-cell lymphomas |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
1555-3892 |
publishDate |
2021-03-01 |
description |
The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT ( n = 20) or MSD-HSCT ( n = 32). All Haplo-HSCT recipients received antithymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis. The median follow-up for all survivors was 38 months. The 100-day cumulative incidence of grade II to IV acute GVHD was similar (19% in the MSD-HSCT group versus 28% in the Haplo-HSCT group, P = 0.52). The 2-year cumulative incidence of chronic GVHD (limited and extensive) after Haplo-HSCT (30%) was also similar with that in the MSD-HSCT group (50%, P = 0.15). The 3-year relapse rates (33% vs 27%, P = 0.84) and non-relapse mortality (21% vs 22%, P = 0.78) did not differ between these two groups. There were also no differences in 3-year overall survival (OS) (48% vs 50%, P = 0.78) and progression-free survival (47% vs 51%, P = 0.95) between these two groups. On multivariate analysis, prognostic index for T-cell lymphoma (PIT) score (higher than 1: hazard ratio [HR], 4.0; P = 0.003) and disease status (stable or progression disease before HSCT: HR, 2.8; P = 0.03) were independent variables associated with worse OS. We concluded that ATG-based haplo-HSCT platform could work as an alternative to MSD-HSCT for patients with PTCLs. |
url |
https://doi.org/10.1177/0963689721999615 |
work_keys_str_mv |
AT guzhenyang myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT linainong myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT wuxiaoxiong myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT wangmaihong myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT fuxiaorui myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT wangzhao myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT renhanyun myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT liyuhang myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT lixiaofan myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT wuyamei myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT liuyao myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT zhangmingzhi myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT wangyini myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT liudaihong myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT dongyujun myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT huliangding myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas AT huangwenrong myeloablativehaploidenticaltransplantasanalternativetomatchedsiblingtransplantforperipheraltcelllymphomas |
_version_ |
1724207164330868736 |